Optimizing TAVI strategy: balancing predilatation benefits and direct implantation efficiency

Future Cardiology · Published 2026-07-23 · DOI 10.1080/14796678.2026.2704403

Free full text

Authors (3)

Ahmed Abdalwahab, Abdalazeem Ibrahem, Mohamed Farag

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Abdalwahab, A., Ibrahem, A., Farag, M. (2026). Optimizing TAVI strategy: balancing predilatation benefits and direct implantation efficiency. Future Cardiology. https://doi.org/10.1080/14796678.2026.2704403

Related articles

• Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study · Future Cardiology · 2026 · Same journal
• A rare and unique case of quadricuspid aortic valve in a patient with triple valve disease and lupus · Future Cardiology · 2026 · Same journal
• Endovascular revascularisation of lower-extremity peripheral arterial disease: technical and clinical outcomes in a Vietnamese single-center prospective cohort study · Future Cardiology · 2026 · Same journal
• Reducing adverse events after percutaneous coronary intervention: the benefits of a personalized approach to dual antiplatelet therapy · Future Cardiology · 2026 · Same journal
• Improvement of respiratory function with acetazolamide in heart failure: a case of cardio-renal pulmonary syndrome · Future Cardiology · 2026 · Same journal
• The Carillon device in the treatment of patients with functional mitral regurgitation · Future Cardiology · 2025 · Same journal
• Advancing coronary artery disease risk stratification: integrating hyperspectral imaging with machine learning for precision cardiology · Future Cardiology · 2025 · Same journal
• Smartwatch detection of atrial flutter and atrial fibrillation: when the apple falls far from the tree - case report · Future Cardiology · 2026 · Same journal
• From bone marrow to the heart: a case report of cardiac involvement in myeloproliferative-associated hypereosinophilic syndrome · Future Cardiology · 2025 · Same journal
• Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction – ARIISE study design · Future Cardiology · 2026 · Same journal